Rise and shine, everyone, another busy day is on the way. The pace has already picked up, as we watch one of the short people dash out the door to the summer job and our official mascot scoots to the nearest corner for a morning nap. As for us, we are busy doing the usual — brewing cups of stimulation (hot buttered rum is our choice today) and foraging for items of interest. Speaking of which, here are a few tidbits to light a spark under you. Hope your day goes well and you conquer the world. And of course, do keep in touch. …

Female chief executives remain exceedingly rare in the drug industry, accounting for less than 10% of biotech’s top leaders, according to BioPharma Dive. Of 180 leading biotechs, just 15 were led by women last year. Two years ago, the BIO trade group set goals for the industry to reach 50% female representation among management and 30% representation on company boards by 2025. No goal was set for the percentage of female chief executives. The top ranks of the industry remain a ways off from those targets.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy